Wedbush assumed coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Get Rating) in a report issued on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $10.00 target price on the stock. Wedbush also issued estimates for ARS Pharmaceuticals' Q4 2022 earnings at ($0.14) EPS, FY2022 earnings at ($1.90) EPS, Q1 2023 earnings at ($0.14) EPS, Q2 2023 earnings at ($0.15) EPS, Q3 2023 earnings at ($0.09) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.44) EPS, FY2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.26 EPS.

Several other analysts have also recently weighed in on the company. William Blair started coverage on ARS Pharmaceuticals in a report on Tuesday, January 3rd. They set an outperform rating and a $17.00 price target for the company. SVB Leerink started coverage on ARS Pharmaceuticals in a report on Tuesday, December 13th. They set an outperform rating and a $14.00 price target for the company.

ARS Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ SPRY opened at $7.05 on Tuesday. ARS Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $9.17. The firm has a market capitalization of $254.22 million, a PE ratio of -2.91 and a beta of 0.07. The company's 50 day moving average is $7.33.

Insiders Place Their Bets

In related news, CFO Kathleen D. Scott acquired 8,250 shares of the stock in a transaction on Tuesday, November 29th. The shares were purchased at an average price of $6.24 per share, for a total transaction of $51,480.00. Following the purchase, the chief financial officer now directly owns 8,250 shares in the company, valued at $51,480. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 34.40% of the company's stock.

ARS Pharmaceuticals Company Profile

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

See Also

• Get a free copy of the StockNews.com research report on ARS Pharmaceuticals (SPRY)
• Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
• Mullen Automotive Stock Gains Momentum On Positive News
• Harley-Davidson Inc. Stock, Is It Time To Buy?
• The Bottom Is In For Meta Platforms, Volatility Is Not Over
• Analyzing Alaska Air's Recent Earnings

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.